Randomized, Placebo-controlled, Double-blind Phase I Dose-escalating Trial to Evaluate the Safety and Immunogenicity of a Vaccine Against Human Cytomegalovirus
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs HB 101 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; First in man
- Sponsors Hookipa Biotech
- 01 Apr 2018 Status changed from active, no longer recruiting to completed.
- 04 May 2017 Results from this trial published in a Hookipa Biotech Media Release.
- 04 May 2017 According to a Hookipa Biotech media release,data from this trial were reviewed by by an independent data and safety monitoring board.